VOLUME 4 (2013)
View Archive »
About The Cover
Targeted radiation therapy disrupts the Brain Tumor’s blood-brain barrier and permits greater penetration of the filomicelle nanocarrier. In Figure 2 (F), Cranial RT is delivered using a novel mouse restrainer and the Small Animal Radiation Research Platform (SARRP). See Baumann et al.
|
|
Table of Contents
Editorial
|
| Protease nexin 1: a novel regulator of prostate cancer cell growth and neoangiogenesis |
|
https://doi.org/10.18632/oncotarget.824
|
| 1-2 |
|
| Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth |
|
https://doi.org/10.18632/oncotarget.841
|
| 3-4 |
|
| The limited contribution of DNA methylation to PMLRARα induced leukemia |
|
https://doi.org/10.18632/oncotarget.875
|
| 5-6 |
Research Papers
|
| MET amplification as a potential therapeutic target in gastric cancer |
|
https://doi.org/10.18632/oncotarget.718
|
| 9-17 |
|
| KDM1 is a novel therapeutic target for the treatment of gliomas |
|
https://doi.org/10.18632/oncotarget.725
|
| 18-28 |
|
| Functional analysis of nonhotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine |
|
https://doi.org/10.18632/oncotarget.755
|
| 29-34 |
|
| SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large BCell Lymphoma DLBCL Patients |
|
https://doi.org/10.18632/oncotarget.774
|
| 35-47 |
|
| Highthroughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion |
|
https://doi.org/10.18632/oncotarget.756
|
| 48-63 |
|
| Enhancing the Efficacy of Drugloaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy |
|
https://doi.org/10.18632/oncotarget.777
|
| 64-79 |
|
| Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition |
|
https://doi.org/10.18632/oncotarget.793
|
| 80-93 |
|
| Intraductal Delivery of Adenoviruses Targets Pancreatic Tumors in Transgenic Elamyc Mice and Orthotopic Xenografts |
|
https://doi.org/10.18632/oncotarget.795
|
| 94-105 |
|
| Quantification of Mesenchymal Stem Cells MSCs at Sites of Human Prostate Cancer |
|
https://doi.org/10.18632/oncotarget.805
|
| 106-117 |
|
| Dual EGFR inhibition in combination with antiVEGF treatment: A phase I clinical trial in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.763
|
| 118-127 |
|
| Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention |
|
https://doi.org/10.18632/oncotarget.786
|
| 128-141 |
|
| Ras inhibition enhances autophagy which partially protects cells from death |
|
https://doi.org/10.18632/oncotarget.703
|
| 142-152 |
|
| Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials |
|
https://doi.org/10.18632/oncotarget.832
|
| 153-162 |
|
| TIMP2 modulates cancer cell transcriptional profile and enhances Ecadherin/betacatenin complex expression in A549 lung cancer cells |
|
https://doi.org/10.18632/oncotarget.801
|
| 163-173 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
